Total hip arthroplasty (THA) is surging worldwide as the gold standard for end-stage hip osteoarthritis, with U.S. volumes alone projected to surpass one million procedures annually by 2040. This growth translates into a rapidly expanding global market, valued at USD 7.4 billion today and forecast to reach nearly USD 10.8 billion by 2030. Using the OE MIND database of 254 studies and 27,000 patients, this analysis highlights Zimmer-Biomet as the clear leader in academic footprint, followed by DePuy Synthes, Stryker, Smith & Nephew, and CeramTec. North America and Europe remain the epicenters of THA research, while China has seen a sharp rise in output over the past five years. In contrast, South America, Africa, the Middle East, and India remain underrepresented, offering opportunities for strategic expansion. With 76 ongoing trials—5 led by Zimmer-Biomet—the field is poised for further evidence generation and innovation.